Eli Lilly, Morphic Deal, Delta Earnings
Bloomberg Intelligence
Eli Lilly's Acquisition Strategy and Industry Innovations
The chapter explores Eli Lilly's $3.2 billion acquisition of Morphic to enhance their immunology franchise by focusing on new technologies and early stage deals. It discusses the pharmaceutical industry's trend of acquiring therapeutics through M&A deals, highlighting Lilly's strategy of bolt-on acquisitions in various therapeutic areas over the past five years. The episode also touches on advancements in different disease fields like obesity, oncology, inflammation, and neurodegenerative diseases, as well as the challenges in developing preventative drugs for complex conditions such as Alzheimer's.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
